Ischemic preconditioning inhibits mitochondrial permeability transition pore opening through the PTEN/PDE4 signaling pathway

Cardiology (Switzerland)

Volumn 129, Issue 3, 2014, Pages 163-173

  Zheng, Xiaoxu ^a   Zu, Lingyun ^a   Becker, Lewis ^a   Cai, Zheqing P ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CL Laboratory   (United States)

Author keywords

Akt; Ischemic preconditioning; Mitochondrial permeability transition pore; PDE4; PTEN

Indexed keywords

CALCIUM ION; CAVEOLIN 3; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PROTEIN KINASE B; ROLIPRAM; SUCROSE; UNCLASSIFIED DRUG; CARRIER PROTEIN; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CAVEOLA; CELL FRACTIONATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SUCROSE DENSITY GRADIENT CENTRIFUGATION; WILD TYPE; ANIMAL; DRUG EFFECTS; HEART INFARCTION PREVENTION; IN VITRO STUDY; INBRED MOUSE STRAIN; KNOCKOUT MOUSE; MALE; METABOLISM; PROCEDURES;

ANIMALS; IN VITRO TECHNIQUES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 4 INHIBITORS; PTEN PHOSPHOHYDROLASE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84910654887     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000363646     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM, et al: Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
2. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007;357:1121-1135.
3. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
4. Hausenloy DJ, Yellon DM: The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 2011;8:619-629.
5. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP: Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-524.
6. Hausenloy DJ, Duchen MR, Yellon DM: Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003;60:617-625.
7. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ: Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-1549.
8. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH: The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-471.
9. Brazil DP, Park J, Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell 2002;111:293-303.
10. Patel HH, Head BP, Petersen HN, Niesman IR, Huang D, Gross GJ, Insel PA, Roth DM: Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and delta-opioid receptors. Am J Physiol 2006;291:H344-H350.
11. Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, Niesman IR, Yokoyama U, Head BP, Hagiwara Y, Ishikawa Y, Miyanohara A, Patel PM, Insel PA, Patel HH, Roth DM: Cardiacspecific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 2008;118:1979-1988.
12. Sun J, Murphy E: Calcium-sensing receptor: a sensor and mediator of ischemic preconditioning in the heart. Am J Physiol 2010;299:H1309-H1317.
13. Tong H, Chen W, Steenbergen C, Murphy E: Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000;87:309-315.
14. Cai ZP, Shen Z, Van Kaer L, Becker LC: Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J 2008;22:4248-4257.
15. Krieg T, Qin Q, Philipp S, Alexeyev MF, Cohen MV, Downey JM: Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol 2004;287:H2606-H2611.
16. Matsui T, Rosenzweig A: Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 2005;38:63-71.
17. Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ: Localization of cardiac L-type Ca (2+) channels to a caveolar macromolecular signaling complex is required for beta (2) - adrenergic regulation. Proc Natl Acad Sci USA 2006;103:7500-7505.
18. Gratton JP, Bernatchez P, Sessa WC: Caveolae and caveolins in the cardiovascular system. Circ Res 2004;94:1408-1417.
19. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, Lisanti MP: Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996;271:2255-2261.
20. Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechêne P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G: Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca 2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 2008;102:1091-1100.
21. Verde I, Vandecasteele G, Lezoualc'h F, Fischmeister R: Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca 2+ current in rat ventricular myocytes. Br J Pharmacol 1999;127:65-74.
22. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR: Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005;123:25-35.
23. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ: Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002;298:834-836.
24. Zu L, Bedja D, Fox-Talbot K, Gabrielson KL, Van Kaer L, Becker LC, Cai ZP: Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. J Mol Cell Cardiol 2010;49:5-15.
25. Zu L, Zheng X, Wang B, Parajuli N, Steenbergen C, Becker LC, Cai ZP: Ischemic preconditioning attenuates mitochondrial localization of PTEN induced by ischemia-reperfusion. Am J Physiol 2011;300:H2177-H2186.
26. Oka N, Asai K, Kudej RK, Edwards JG, Toya Y, Schwencke C, Vatner DE, Vatner SF, Ishikawa Y: Downregulation of caveolin by chronic beta-adrenergic receptor stimulation in mice. Am J Physiol 1997;273:C1957-C1962.
27. Talukder MA, Kalyanasundaram A, Zhao X, Zuo L, Bhupathy P, Babu GJ, Cardounel AJ, Periasamy M, Zweier JL: Expression of SERCA isoform with faster Ca 2+ transport properties improves postischemic cardiac function and Ca 2+ handling and decreases myocardial infarction. Am J Physiol 2007;293:H2418-H2428.
28. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P, Di Lisa F: Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 1999;76:725-734.
29. Cai Z, Semenza GL: PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 2005;97:1351-1359.
30. Ruan H, Li J, Ren S, Gao J, Li G, Kim R, Wu H, Wang Y: Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J Mol Cell Cardiol 2009;46:193-200.
31. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737-749.
32. Kunuthur SP, Mocanu MM, Hemmings BA, Hausenloy DJ, Yellon DM: The Akt1 isoform is an essential mediator of ischaemic preconditioning. J Cell Mol Med 2012;16:1739-1749.
33. Mocanu MM, Bell RM, Yellon DM: PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 2002;34:661-668.
34. 2+ channel CaV1.2 via the β-adrenergic-cAMP-protein kinase A pathway: old dogmas, advances, and new uncertainties. Circ Res 2013;113:617-631.
35. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, Santana LF, McKnight GS: Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res 2010;107:747-756.
36. Xiang Y, Naro F, Zoudilova M, Jin SL, Conti M, Kobilka B: Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci USA 2005;102:909-914.
37. Tong H, Bernstein D, Murphy E, Steenbergen C: The role of beta-adrenergic receptor signaling in cardioprotection. FASEB J 2005;19:983-985.
38. Bjørgo E, Solheim SA, Abrahamsen H, Baillie GS, Brown KM, Berge T, Okkenhaug K, Houslay MD, Taskén K: Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase A signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol 2010;30:1660-1672.
39. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM: Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol 2005;288:H971-H976.
40. Murphy E, Steenbergen C: Mechanisms underlying acute protection from cardiac ischemiareperfusion injury. Physiol Rev 2008;88:581-609.
41. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against ischemiareperfusion injury in mouse heart. Circulation 2000;101:660-667.
42. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J, Xiao RP: MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 2010;121:2565-2574.
43. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ: Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009;104:1240-1252.